The global Anti-tumor Drug market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.
Anti-tumor drugs are for the treatment of cancer diseases. In recent years, the development of molecular oncology and molecular pharmacology has gradually clarified the nature of the tumor. The invention and application of advanced technologies such as large-scale rapid screening, combinatorial chemistry and genetic engineering have accelerated the process of drug development. The research and development of anti-tumor drugs have been into a new era.
In China, Anti-tumor Drug key players include AstraZeneca, Merck & Co., Roche, Celgene, Johnson & Johnson, etc.
United States is the largest market, followed by Japan, and Europe.
This report is a detailed and comprehensive analysis for global Anti-tumor Drug market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Anti-tumor Drug market size and forecasts, in consumption value ($ Million), 2020-2031
Global Anti-tumor Drug market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Anti-tumor Drug market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Anti-tumor Drug market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Anti-tumor Drug
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Anti-tumor Drug market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Novartis, Celgene, Bristol-Myers Squibb, Amgen, Johnson & Johnson, Pfizer, Takeda, Eli Lilly, AstraZeneca, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 segmentation
Anti-tumor Drug market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Cytotoxic Drugs
Non-cytotoxic Drugs
麻豆原创 segment by Application
Alkylating Agents
Anti-Metabolism Drugs
Platinum Antineoplastic Agents
Anthracycline Antitumor Drugs
Microtubule Stabilizer
Endocrine Therapy Drugs
Immunotherapy Drugs
Gene Therapy Drugs
Targeted Antineoplastic Drugs
麻豆原创 segment by players, this report covers
Roche
Novartis
Celgene
Bristol-Myers Squibb
Amgen
Johnson & Johnson
Pfizer
Takeda
Eli Lilly
AstraZeneca
Astellas
Merck & Co
Sanofi
Bayer
Biogen Idec
Eisai
Teva
Otsuka
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Anti-tumor Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Anti-tumor Drug, with revenue, gross margin, and global market share of Anti-tumor Drug from 2020 to 2025.
Chapter 3, the Anti-tumor Drug competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Anti-tumor Drug market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Anti-tumor Drug.
Chapter 13, to describe Anti-tumor Drug research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Anti-tumor Drug by Type
1.3.1 Overview: Global Anti-tumor Drug 麻豆原创 Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Anti-tumor Drug Consumption Value 麻豆原创 Share by Type in 2024
1.3.3 Cytotoxic Drugs
1.3.4 Non-cytotoxic Drugs
1.4 Global Anti-tumor Drug 麻豆原创 by Application
1.4.1 Overview: Global Anti-tumor Drug 麻豆原创 Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Alkylating Agents
1.4.3 Anti-Metabolism Drugs
1.4.4 Platinum Antineoplastic Agents
1.4.5 Anthracycline Antitumor Drugs
1.4.6 Microtubule Stabilizer
1.4.7 Endocrine Therapy Drugs
1.4.8 Immunotherapy Drugs
1.4.9 Gene Therapy Drugs
1.4.10 Targeted Antineoplastic Drugs
1.5 Global Anti-tumor Drug 麻豆原创 Size & Forecast
1.6 Global Anti-tumor Drug 麻豆原创 Size and Forecast by Region
1.6.1 Global Anti-tumor Drug 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Anti-tumor Drug 麻豆原创 Size by Region, (2020-2031)
1.6.3 North America Anti-tumor Drug 麻豆原创 Size and Prospect (2020-2031)
1.6.4 Europe Anti-tumor Drug 麻豆原创 Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Anti-tumor Drug 麻豆原创 Size and Prospect (2020-2031)
1.6.6 South America Anti-tumor Drug 麻豆原创 Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Anti-tumor Drug 麻豆原创 Size and Prospect (2020-2031)
2 Company Profiles
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche Anti-tumor Drug Product and Solutions
2.1.4 Roche Anti-tumor Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Roche Recent Developments and Future Plans
2.2 Novartis
2.2.1 Novartis Details
2.2.2 Novartis Major Business
2.2.3 Novartis Anti-tumor Drug Product and Solutions
2.2.4 Novartis Anti-tumor Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 Novartis Recent Developments and Future Plans
2.3 Celgene
2.3.1 Celgene Details
2.3.2 Celgene Major Business
2.3.3 Celgene Anti-tumor Drug Product and Solutions
2.3.4 Celgene Anti-tumor Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 Celgene Recent Developments and Future Plans
2.4 Bristol-Myers Squibb
2.4.1 Bristol-Myers Squibb Details
2.4.2 Bristol-Myers Squibb Major Business
2.4.3 Bristol-Myers Squibb Anti-tumor Drug Product and Solutions
2.4.4 Bristol-Myers Squibb Anti-tumor Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.5 Amgen
2.5.1 Amgen Details
2.5.2 Amgen Major Business
2.5.3 Amgen Anti-tumor Drug Product and Solutions
2.5.4 Amgen Anti-tumor Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 Amgen Recent Developments and Future Plans
2.6 Johnson & Johnson
2.6.1 Johnson & Johnson Details
2.6.2 Johnson & Johnson Major Business
2.6.3 Johnson & Johnson Anti-tumor Drug Product and Solutions
2.6.4 Johnson & Johnson Anti-tumor Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 Johnson & Johnson Recent Developments and Future Plans
2.7 Pfizer
2.7.1 Pfizer Details
2.7.2 Pfizer Major Business
2.7.3 Pfizer Anti-tumor Drug Product and Solutions
2.7.4 Pfizer Anti-tumor Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 Pfizer Recent Developments and Future Plans
2.8 Takeda
2.8.1 Takeda Details
2.8.2 Takeda Major Business
2.8.3 Takeda Anti-tumor Drug Product and Solutions
2.8.4 Takeda Anti-tumor Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 Takeda Recent Developments and Future Plans
2.9 Eli Lilly
2.9.1 Eli Lilly Details
2.9.2 Eli Lilly Major Business
2.9.3 Eli Lilly Anti-tumor Drug Product and Solutions
2.9.4 Eli Lilly Anti-tumor Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 Eli Lilly Recent Developments and Future Plans
2.10 AstraZeneca
2.10.1 AstraZeneca Details
2.10.2 AstraZeneca Major Business
2.10.3 AstraZeneca Anti-tumor Drug Product and Solutions
2.10.4 AstraZeneca Anti-tumor Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.10.5 AstraZeneca Recent Developments and Future Plans
2.11 Astellas
2.11.1 Astellas Details
2.11.2 Astellas Major Business
2.11.3 Astellas Anti-tumor Drug Product and Solutions
2.11.4 Astellas Anti-tumor Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.11.5 Astellas Recent Developments and Future Plans
2.12 Merck & Co
2.12.1 Merck & Co Details
2.12.2 Merck & Co Major Business
2.12.3 Merck & Co Anti-tumor Drug Product and Solutions
2.12.4 Merck & Co Anti-tumor Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.12.5 Merck & Co Recent Developments and Future Plans
2.13 Sanofi
2.13.1 Sanofi Details
2.13.2 Sanofi Major Business
2.13.3 Sanofi Anti-tumor Drug Product and Solutions
2.13.4 Sanofi Anti-tumor Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.13.5 Sanofi Recent Developments and Future Plans
2.14 Bayer
2.14.1 Bayer Details
2.14.2 Bayer Major Business
2.14.3 Bayer Anti-tumor Drug Product and Solutions
2.14.4 Bayer Anti-tumor Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.14.5 Bayer Recent Developments and Future Plans
2.15 Biogen Idec
2.15.1 Biogen Idec Details
2.15.2 Biogen Idec Major Business
2.15.3 Biogen Idec Anti-tumor Drug Product and Solutions
2.15.4 Biogen Idec Anti-tumor Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.15.5 Biogen Idec Recent Developments and Future Plans
2.16 Eisai
2.16.1 Eisai Details
2.16.2 Eisai Major Business
2.16.3 Eisai Anti-tumor Drug Product and Solutions
2.16.4 Eisai Anti-tumor Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.16.5 Eisai Recent Developments and Future Plans
2.17 Teva
2.17.1 Teva Details
2.17.2 Teva Major Business
2.17.3 Teva Anti-tumor Drug Product and Solutions
2.17.4 Teva Anti-tumor Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.17.5 Teva Recent Developments and Future Plans
2.18 Otsuka
2.18.1 Otsuka Details
2.18.2 Otsuka Major Business
2.18.3 Otsuka Anti-tumor Drug Product and Solutions
2.18.4 Otsuka Anti-tumor Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.18.5 Otsuka Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Anti-tumor Drug Revenue and Share by Players (2020-2025)
3.2 麻豆原创 Share Analysis (2024)
3.2.1 麻豆原创 Share of Anti-tumor Drug by Company Revenue
3.2.2 Top 3 Anti-tumor Drug Players 麻豆原创 Share in 2024
3.2.3 Top 6 Anti-tumor Drug Players 麻豆原创 Share in 2024
3.3 Anti-tumor Drug 麻豆原创: Overall Company Footprint Analysis
3.3.1 Anti-tumor Drug 麻豆原创: Region Footprint
3.3.2 Anti-tumor Drug 麻豆原创: Company Product Type Footprint
3.3.3 Anti-tumor Drug 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Anti-tumor Drug Consumption Value and 麻豆原创 Share by Type (2020-2025)
4.2 Global Anti-tumor Drug 麻豆原创 Forecast by Type (2026-2031)
5 麻豆原创 Size Segment by Application
5.1 Global Anti-tumor Drug Consumption Value 麻豆原创 Share by Application (2020-2025)
5.2 Global Anti-tumor Drug 麻豆原创 Forecast by Application (2026-2031)
6 North America
6.1 North America Anti-tumor Drug Consumption Value by Type (2020-2031)
6.2 North America Anti-tumor Drug 麻豆原创 Size by Application (2020-2031)
6.3 North America Anti-tumor Drug 麻豆原创 Size by Country
6.3.1 North America Anti-tumor Drug Consumption Value by Country (2020-2031)
6.3.2 United States Anti-tumor Drug 麻豆原创 Size and Forecast (2020-2031)
6.3.3 Canada Anti-tumor Drug 麻豆原创 Size and Forecast (2020-2031)
6.3.4 Mexico Anti-tumor Drug 麻豆原创 Size and Forecast (2020-2031)
7 Europe
7.1 Europe Anti-tumor Drug Consumption Value by Type (2020-2031)
7.2 Europe Anti-tumor Drug Consumption Value by Application (2020-2031)
7.3 Europe Anti-tumor Drug 麻豆原创 Size by Country
7.3.1 Europe Anti-tumor Drug Consumption Value by Country (2020-2031)
7.3.2 Germany Anti-tumor Drug 麻豆原创 Size and Forecast (2020-2031)
7.3.3 France Anti-tumor Drug 麻豆原创 Size and Forecast (2020-2031)
7.3.4 United Kingdom Anti-tumor Drug 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Russia Anti-tumor Drug 麻豆原创 Size and Forecast (2020-2031)
7.3.6 Italy Anti-tumor Drug 麻豆原创 Size and Forecast (2020-2031)
8 Asia-Pacific
8.1 Asia-Pacific Anti-tumor Drug Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Anti-tumor Drug Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Anti-tumor Drug 麻豆原创 Size by Region
8.3.1 Asia-Pacific Anti-tumor Drug Consumption Value by Region (2020-2031)
8.3.2 China Anti-tumor Drug 麻豆原创 Size and Forecast (2020-2031)
8.3.3 Japan Anti-tumor Drug 麻豆原创 Size and Forecast (2020-2031)
8.3.4 South Korea Anti-tumor Drug 麻豆原创 Size and Forecast (2020-2031)
8.3.5 India Anti-tumor Drug 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Southeast Asia Anti-tumor Drug 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Australia Anti-tumor Drug 麻豆原创 Size and Forecast (2020-2031)
9 South America
9.1 South America Anti-tumor Drug Consumption Value by Type (2020-2031)
9.2 South America Anti-tumor Drug Consumption Value by Application (2020-2031)
9.3 South America Anti-tumor Drug 麻豆原创 Size by Country
9.3.1 South America Anti-tumor Drug Consumption Value by Country (2020-2031)
9.3.2 Brazil Anti-tumor Drug 麻豆原创 Size and Forecast (2020-2031)
9.3.3 Argentina Anti-tumor Drug 麻豆原创 Size and Forecast (2020-2031)
10 Middle East & Africa
10.1 Middle East & Africa Anti-tumor Drug Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Anti-tumor Drug Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Anti-tumor Drug 麻豆原创 Size by Country
10.3.1 Middle East & Africa Anti-tumor Drug Consumption Value by Country (2020-2031)
10.3.2 Turkey Anti-tumor Drug 麻豆原创 Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Anti-tumor Drug 麻豆原创 Size and Forecast (2020-2031)
10.3.4 UAE Anti-tumor Drug 麻豆原创 Size and Forecast (2020-2031)
11 麻豆原创 Dynamics
11.1 Anti-tumor Drug 麻豆原创 Drivers
11.2 Anti-tumor Drug 麻豆原创 Restraints
11.3 Anti-tumor Drug Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Anti-tumor Drug Industry Chain
12.2 Anti-tumor Drug Upstream Analysis
12.3 Anti-tumor Drug Midstream Analysis
12.4 Anti-tumor Drug Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Roche
Novartis
Celgene
Bristol-Myers Squibb
Amgen
Johnson & Johnson
Pfizer
Takeda
Eli Lilly
AstraZeneca
Astellas
Merck & Co
Sanofi
Bayer
Biogen Idec
Eisai
Teva
Otsuka
听
听
*If Applicable.
